Find Federal Grants
Investigating the in vivo behavior and in vitro characteristics purportedly gastro-retentive extended release formulation to enhance the regulatory standard of such products
Food and Drug Administration · RFA-FD-22-018
Cutaneous pharamcokinetic-based approaches to establish bioequivalence of topically applied drug products
Food and Drug Administration · RFA-FD-22-017
Building an Integrated Information Technology Infrastructure for State Regulatory Programs (U2F) [Clinical Trial Not Allowed]
Food and Drug Administration · RFA-FD-22-021
Research to support the development of alternatives to antimicrobials for use in food-producing animals
Food and Drug Administration · PAR-22-087
Food and Drug Administration · PAR-22-063
Conformance with the Egg Regulatory Program Standards (U2F) [Clinical Trial Not Allowed]
Food and Drug Administration · RFA-FD-22-006
Renewal - Cooperative Agreement to Support the Joint Institute for Food Safety and Applied Nutrition, JIFSAN (U01) Clinical Trial Not Allowed
Food and Drug Administration · RFA-FD-22-004
AmeriCorps · AC-11-01-21
Pool Safely Grant Program
Consumer Product Safety Commission · CP-VGB-21-001
Food and Drug Administration · RFA-FD-22-003
Enhance Uniformity of Traffic Laws and Countermeasures Among State Motor Vehicle Administrators Offices
National Highway Traffic Safety Administration · 693JJ921R000002
Pool Safely Grant Program (PSGP)
Consumer Product Safety Commission · CPSC-21-001
Food and Drug Administration · FOR-FD-21-007
Enhancing Innovations in Advanced Manufacturing Technologies for Vaccines against Influenza and Emerging Infectious Diseases
Food and Drug Administration · FOR-FD-21-006
Food and Drug Administration · FOR-FD-21-004
Food and Drug Administration · FOR-FD-20-031
Development of a model selection method for population pharmacokinetics analysis by deep-learning based reinforcement learning
Food and Drug Administration · FOR-FD-20-030
Expanding the Opioids System Model to more comprehensively incorporate fentanyl, stimulants use, polysubstance use and associated outcomes.
Food and Drug Administration · FOR-FD-20-029
Dermal Physiologically-Based Pharmacokinetic (PBPK) Models Accounting for the Absorption and Evaporation of Vehicle/Co-Solvent Following the Application of Generic Dermatological Products
Food and Drug Administration · FOR-FD-20-027
Impulse Oscillometry Endpoint Sensitivity to Regional Lung Function Changes using Computational Fluid Dynamics (CFD)
Food and Drug Administration · FOR-FD-20-028